## Diabetic Ketoacidosis (DKA) Emergency Department 2 Bag System Care Guideline



#### Inclusion Criteria (Definition of DKA):

- Blood glucose (BG) > 200 mg/dl
- Acidosis (bicarbonate < 15 or blood gas pH < 7.3)</li>
- Associated glycosuria, ketonuria & ketonemia

**Requires Critical Care level of care** 

If patient is wearing an insulin pump – remove pump, cannula and tubing

#### **Initial Evaluation**

Assessment: VS, weight, severity of dehydration, level of consciousness, acute trigger for DKA (e.g. infection, trauma, failure to take insulin, pump failure)

Laboratory: Stat bedside BG, BMP, phosphorous, magnesium, venous pH, pCO2, pO2, CBC, UA, appropriate cultures if infection suspected. (HbA1c only if new onset DM/

Give 10-20 mL/kg of 0.9% normal saline (NS), administer over one hour For overt shock – consider giving up to 40mL/kg

# Insulin Drip Ensure K level WNL prior to starting insulin drip

Starting dose 0.05 to 0.1 units/kg/hr Titrate insulin by 0.01 units/kg/hr to keep Blood Glucose between 150-300

**Ongoing Monitoring** 

BMP every 2 hours X 3 then every 4 hours

BP, HR, RR

if improving

Neuro checks every hour

Bedside BG every hour

Progress to 2 Bag System
Starting with Phase 1
On page 2

### Neuro checks for S/S of cerebral edema every hour

### **Cerebral Edema Signs and Symptoms**

- Headache
- Altered or fluctuating level of consciousness
- Sustained heart rate deceleration
- Abnormal and deteriorating neurological exam
- Abnormal respiratory pattern
- Recurrent vomiting
- Rising blood pressure
- Decreased oxygen saturation
- Change in neuro status
- Restlessness

#### **Cerebral Edema Treatment**

- Give mannitol 0.5 gm/kg may be repeated X 1 for a total max of 50 gm
- Ensure adequate circulation but if possible reduce fluid rate by one third
- Avoid maneuvers and drugs likely to increase intracranial pressure
- If intubation is necessary consider neurosurgery consult for intracranial pressure monitoring
- Treat suspected cerebral edema based on clinical criteria immediately. Do not delay treatment to obtain confirmatory CT scan.

#### **Recommendations/Considerations**

- The severity of DKA is defined by the degree of acidosis: mild pH 7.2 7.3; moderate pH 7.1 7.2; severe pH < 7.1</li>
- Goal decrease in glucose no more than 100 mg/dl per hour
- If glucose decreases rapidly this may increase the risk of cerebral edema
- Monitor Na level correction to ensure NA rises as glucose decreases using calculation of corrected Na level

#### Severity of dehydration:

- 5% reduced skin turgor, dry mucous membranes, tachycardia
- 10% capillary refill ≥ 3 seconds, sunken eyes
- >10% weak or impalpable peripheral pulses, hypotension, shock, oliguria

#### **Calculations:**

- Anion gap = Na − (Cl+HCO3); normal is 12 ± 2 mmol/l
- Corrected sodium = measured Na + 1.6 X [(glucose mg/dl 100) / 100]
- DKA at diagnosis is more common in children < 5 yrs of age
- Omission of insulin is the leading cause of recurrent DKA in adolescents

#### **Causes of Morbidity and Mortality:**

- Cerebral edema, which occurs in 0.5 1 % of all episodes of DKA, is the most common cause of mortality in children with DKA, Cerebral edema usually develops 4 – 12 hours into treatment, but it can occur at any time
- Hypokalemia
- Na Bicarb should not be given without discussion with two attending physicians as this increases the risk of cerebral edema.
- For insulin drip, tubing must be manually primed.


### **Correction of Dehydration**

- Estimate fluid deficit
- · Subtract initial bolus received
- Divide remaining deficit over 48 hours
- Add deficit replacement/hour to normal maintenance/hr = Total fluid rate per hour
- Re-evaluate I/O for excessive ongoing urine loss
- Do not bolus > 40 mL/kg in 4 hours unless hypotensive or has significantly compromised perfusion

#### **Principals of 2 Bag System**

- Total fluid rate is dependent on amount needed for treatment of dehydration as above (usually around 1.5 X maintenance)
- Using 2 bags allows for change in glucose infusion rate without ordering multiple IV bags
- Insulin drip rate is adjusted to ensure resolution of acidosis

   0.05-0.12 unit/kg/hr
- Do not decrease insulin rate below 0.05 unit/kg/hr without discussion with Endocrinologist on-call






# Diabetic Ketoacidosis (DKA) Emergency Department 2 Bag System Care Guideline



Individual rates of Bag 1 and Bag 2 are dependent on glucose level with goal of maintaining glucose of 150-300.

Total rate depends on fluid needs.

		Bag 1	Bag 2		
	Plasma Glucose	NS	D10 ½ NS	Final Dextrose	Final NaCL
				Concentration %	Concentration
Start Phase 1	>300	100%	0%	0	NS
Once BG <300	225-300	50%	50%	5	34 NS
Phase 2					
Phase 3	150 – 224	25%	75%	7.5	2/3 NS
Phase 4	100 – 149	0%	100%	10	½ NS
	<100	Change to D12.5% with ½ NS + K and hold insulin drip for 30 minutes until BG > 150			







# References Diabetic Ketoacidosis (DKA) Emergency Department 2 Bag System Care Guideline

Bakes K, Haukoos JS, Deakyne SJ, et al. Effect of volume of fluid resuscitation on metabolic normalization in children presenting in diabetic ketoacidosis: A randomized controlled trial. Journal of Emergency Medicine 2016;50(4):551-559. http://dx.doi.org/10.1016/j.jemermed.2015.12.003 (Level II)

Baumer-Mouradian SH, Gray MP, Wolfgram PM et al. Improving emergency department management of diabetic ketoacidosis in children. Pediatrics 2019;144(4). http://dx.doi.org/10.1542/peds.2018-2984 (Level V)

Dunger DB, Sperling MA, Acerini CL, *et al* ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Archives of Disease in Childhood 2004;89(2):188-194. http://dx.doi.org/10.1136/adc.2003.044875 (**Level V**)

Fagan MJ, Avner J, Khine H. Initial fluid resuscitation for patients with diabetic ketoacidosis: How dry are they? Clinical Pediatrics 2008; 47(9):851-855. http://dx.doi.org/10.1177/0009922808319960 (Level V)

Felner EI, White PC. Improving management of diabetic ketoacidosis in children. Pediatrics 2001;108(3):735-740. http://dx.doi.org/10.1542/peds.108.3.735 (Level V)

Flood K, Nour M, Hold T, et al. Implementation and evaluation of a diabetic ketoacidosis order set in pediatric type 1 diabetes at a teriary care hospital: A quality-improvement initiative. Canadian Journal of Diabetes 2019;43(5):297-303. http://dx.doi.org/10.1016/j.cjd.2018.12.005 (Level V)

Glaser N. Pediatric diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatric Clinics of North America 2005;52(6):1611-1635. http://dx.doi.org/10.1016/j.pcl.2005.09.001 (Level V)

Glaser N, Kuppermann N. Fluid treatment for children with diabetic ketoacidosis: How do the results of the pediatric emergency care applied research network Fluids Therapies Under Investigation in Diabetic Ketoacidosis (FLUID) Trial change our perspective? Pediatric Diabetes 2019;20:10-14. http://dx.doi.org/10.111/pedi.12795 (Level V)

Koul PB. Diabetic ketoacidosis: A current appraisal of pathophysiology and management. Clinical Pediatrics 2009; 48(2):135-144. http://dx.doi.org/10.1177/0009922808323907 (Level V)

Lavoie ME. Management of a patient with diabetic ketoacidosis in the emergency department. Pediatric Emergency Care 2015;31(5):376-383. (Level V)

Long B, Koyfman A. Emergency medicine myths: Cerebral edema in pediatric diabetic ketoacidosis and intravenous fluids. Journal of Emergency Medicine 2017; 53(2):212-221. http://dx.doi.org/10.1016/j.jemermed.2017.03.014 (Level V)

Pruitt LG, Jones G, Musso M, et al. Intravenous fluid bolus rates and pediatric diabetic ketoacidosis resolution. American Journal of Emergency Medicine 2019;37:2239-2241. http://dx.doi.org/10.1016/j.ajem.2019.03.039 (Level V)

Wolfsdorf J, Glaser N, Sperling MA. Diabetic ketoacidosis in infants, children, and adolescents. A consensus statement from the American Diabetes Association. Diabetes Care, May 2006;29(5):1150-1159. https://doi.org/10.2337/dc06-9909 (Level V)

Zee-Cheng JE, Webber EC, Abu-Sultaneh S. Adherence to pediatric diabetic ketoacidosis guidelines by community emergency departments' providers. International Journal of Emergency Medicine 2017;10(11);1-5. http://dx.doi.org/10.1186/s12245-017-0137-8 (Level V)

Reviewed by Evidence-Based Medicine Committee - 9/16/2020

